A Vaccine for Parkinson's Disease in Clinical Trials

[jimcaster]

cureparkinsons.org.uk/news/...

[kalyan48]

I thought MANNITOL does clear alpha-synuclien

[WinnieThePoo]

Not sure if vaccine is the right term. Vaccines stimulate the body to produce antibodies. This is an antibody (a monoclonal alpha-synuclein antibody). It is the same principle as the product I am about to trial. It may even be that product (although this looks like a USA only trial). I know it sounds a bit daft but my neurologist at Toulouse explained in detail what the antibody did, and what the trial involved, but I forgot to ask specifically which product it was.

I sort of assumed my trial is this one

ichgcp.net/clinical-trials-...

The French have their own way of doing things, and I am due to be contacted "soon" (a term the French understand differently from Anglo Saxons)

[felixned in reply to WinnieThePoo]

There are two companies that have immunotherapy drugs in clinical trials: one you mentioned - Prothena which was bought by La Roche (?) and Affiris - an Austrian company. If you want to know more about these check out Simon's site:

scienceofparkinsons.com/201...

Prothena Phase 1 results were published and it appears to be quite effective in reducing ASNs. It is interesting that concentration of antibodies in CSF (spinal fluid) was only .2 or .3%.

One thing that is often missed: toxicity of misfolded ASNs is a theory not a fact. There are plenty of data that point to ASN as the "bad guy" but there are those who think ASN is just a byproduct of cell defense mechanism. There are two interesting facts: "normal" ASN constitutes 3% of our brains (that's a lot) and not everybody who has misfolded ASNs has PD. Hopefully these trials will give a definitive answer to the role bad ASN play in PD.

[WinnieThePoo in reply to felixned]

It's quite an extensive theory regarding ASN. Have you also seen the Bristol University research regarding ASN and mir7?